Overview

Gender

male

Mark Bodmer joined Evelo as Chief Scientific Officer and president of R&D from UCB where he was head of New Medicines Therapeutics leading UCB's research in immunology, neurology and bone disease. Prior to joining UCB, he served as senior vice president of immunoinflammation, at GlaxoSmithKline, where he was also previously head of metabolic and cardiovascular disease drug discovery. Mark previously served as the chief executive officer at three biotech companies: Hexagen, Lorantis, and Biotica. He received his Ph.D. from Cambridge University.